Update shared on 03 Dec 2025
Analysts have nudged their price target on Jeena Sikho Lifecare slightly higher to align with an updated fair value estimate of ₹950.00, reflecting confidence in the company’s projected revenue growth and stable profit margins.
What's in the News
- A board meeting is scheduled on November 6, 2025, to review and approve unaudited financial results for the quarter ended September 30, 2025, and to address other business with the chairperson's approval (company filing).
- The Pet Yakrit Pleeha Shuddhi Kit has been launched nationally, extending the Pet Shuddhi product line across India through the Jeena Sikho Hospitals Network to support detoxification and organ health (press conference, New Delhi).
- An exclusive five-year diagnostic collaboration has been signed with Chandan Healthcare Limited, making Chandan the official diagnostic partner across all existing and future Jeena Sikho hospitals, clinics, and wellness centers (board resolution).
- A final dividend of INR 1.10 per equity share (face value INR 2) has been declared for FY 2024–2025 at the AGM held on September 29, 2025 (AGM outcome).
- A wholly owned UAE subsidiary, Jeena Sikho International LLC, has been incorporated in the Sharjah Media City Free Zone, with a business license valid until September 10, 2027, to expand healthcare and consultancy services in the region (regulatory disclosure).
Valuation Changes
- Fair Value Estimate is maintained at ₹950.00 per share, indicating no material change in the intrinsic value assessment.
- The Discount Rate is unchanged at 12.76 percent, suggesting the risk profile and required return assumptions remain stable.
- Revenue Growth is effectively steady at about 45.57 percent, with only rounding refinements in the updated model.
- The Net Profit Margin is virtually unchanged at around 26.85 percent, reflecting continued expectations of stable profitability.
- The Future P/E is maintained at approximately 32.68 times, signaling no notable shift in the long term earnings multiple applied.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.